Effects of neoadjuvant VEGF-TKI treatment on surgery for renal cell carcinoma: A systematic review and meta-analysis

被引:2
|
作者
Zhu, Meikai [1 ]
Liu, Zhifeng [2 ]
Zhou, Yongheng [1 ]
Jiang, Zhiwen [1 ]
Chen, Shouzhen [1 ]
Wang, Wenfu [1 ]
Shi, Benkang [1 ]
Zhu, Yaofeng [1 ]
机构
[1] Shandong Univ, Qilu Hosp, Dept Urol, 107 Wenhua West Rd, Jinan 250012, Shandong, Peoples R China
[2] Taian City Cent Hosp, Dept Urol, Tai An 271000, Shandong, Peoples R China
关键词
neoadjuvant therapy; targeted therapy; renal cell carcinoma; surgical treatment; nephrectomy; TARGETED MOLECULAR THERAPIES; VENA-CAVA THROMBECTOMY; PARTIAL NEPHRECTOMY; TUMOR THROMBUS; SUNITINIB; SORAFENIB; AXITINIB; CANCER; TRIAL;
D O I
10.3892/ol.2024.14295
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To evaluate the effects of neoadjuvant vascular endothelial growth factor-tyrosine kinase inhibitor (VEGF-TKI) treatment on surgery in patients with renal cell carcinoma (RCC), sources from Embase, PubMed and the Cochrane Library databases collected from inception to December, 2022 were used for analysis in the present study, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Data regarding surgical outcomes were collected. The pooled effect sizes were calculated in terms of the risk ratio (RR)/standard mean difference (SMD) with 95% confidence intervals (CIs) using the random-effects model. Subgroup and sensitivity analyses were used to explore the source of heterogeneity within the data. In total, 9 identified articles involving 829 patients (336 in the neoadjuvant + surgery group; 493 in the surgery group) were included in the present study, according to the criteria. The results demonstrated that there were no significant differences in blood loss (SMD=-0.11; 95% CI, -0.63-0.41; P=0.68), postoperative length of hospital stay or total length of hospital stay (SMD=0.23; 95% CI, -0.55-1.01; P=0.57) or complications (RR=1.16; 95% CI, 0.80-1.67; P=0.44) between the two groups. However, neoadjuvant therapy reduced the operation time (SMD=-0.67; 95% CI, -1.25- -0.09; P=0.02) and resulted in a greater proportion of patients choosing partial nephrectomy (RR=1.84; 95% CI, 1.47-2.31; P<0.00001). In the subgroup analysis, the blood loss was significantly lower in patients with RCC with inferior vena cava tumor thrombus in the neoadjuvant group (SMD=-1.10; 95% CI, -1.82- -0.38; P=0.003). In conclusion, the results of the present study indicated that neoadjuvant VEGF-TKI treatment in patients with RCC shortened operation time, decreased blood loss and did not cause an increase in perioperative complications. In addition, this treatment modality may encourage patients to opt for partial nephrectomy to preserve renal function.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Neoadjuvant therapy in renal cell carcinoma with tumor thrombus: A systematic review and meta-analysis
    Gu, Liangyou
    Peng, Cheng
    Li, Huaikang
    Jia, Tongyu
    Chen, Xinran
    Wang, Hanfeng
    Du, Songliang
    Tang, Lu
    Liang, Qiyang
    Wang, Baojun
    Ma, Xin
    Zhang, Xu
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 196
  • [2] Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma
    Sharma, Revati
    Kadife, Elif
    Myers, Mark
    Kannourakis, George
    Prithviraj, Prashanth
    Ahmed, Nuzhat
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021, 40 (01)
  • [3] Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma
    Revati Sharma
    Elif Kadife
    Mark Myers
    George Kannourakis
    Prashanth Prithviraj
    Nuzhat Ahmed
    Journal of Experimental & Clinical Cancer Research, 40
  • [4] ADJUVANT THERAPY AFTER SURGERY IN RENAL CELL CARCINOMA: SYSTEMATIC REVIEW WITH META-ANALYSIS
    Reis, Leonardo O., Sr.
    Scherr, A. J. O.
    Sasse, E. C.
    Lima, C. S. P.
    Lima, J. P.
    Sasse, A. D.
    Ferreira, Ubirajara, Sr.
    JOURNAL OF UROLOGY, 2009, 181 (04): : 501 - 502
  • [5] High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors?
    Fallara, Giuseppe
    Bandini, Marco
    Larcher, Alessandro
    Pederzoli, Filippo
    Karakiewicz, Pierre
    Tian, Zhe
    Briganti, Alberto
    Necchi, Andrea
    Salonia, Andrea
    Bertini, Roberto
    Montorsi, Francesco
    Bex, Axel
    Capitanio, Umberto
    CURRENT PROBLEMS IN CANCER, 2021, 45 (06)
  • [6] Effects of VEGF and VEGFR polymorphisms on the outcome of patients with metastatic renal cell carcinoma treated with sunitinib: a systematic review and meta-analysis
    Miao, Chenkui
    Cao, Jingyi
    Wang, Yuhao
    Liu, Bianjiang
    Wang, Zengjun
    ONCOTARGET, 2017, 8 (40) : 68854 - 68862
  • [7] Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: A systematic review and meta-analysis
    Winquist, E
    Kirchner, TS
    Segal, R
    Chin, J
    Lukka, H
    JOURNAL OF UROLOGY, 2004, 171 (02): : 561 - 569
  • [8] Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: A systematic review and meta-analysis
    Malik, B.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Radiomics in Renal Cell Carcinoma-A Systematic Review and Meta-Analysis
    Muhlbauer, Julia
    Egen, Luisa
    Kowalewski, Karl-Friedrich
    Grilli, Maurizio
    Walach, Margarete T.
    Westhoff, Niklas
    Nuhn, Philipp
    Laqua, Fabian C.
    Baessler, Bettina
    Kriegmair, Maximilian C.
    CANCERS, 2021, 13 (06) : 1 - 15
  • [10] Adjuvant immunotherapy in renal cell carcinoma: a systematic review and meta-analysis
    Riveros, Carlos
    Huang, Emily
    Ranganathan, Sanjana
    Klaassen, Zachary
    Rini, Brian
    Wallis, Christopher J. D.
    Satkunasivam, Raj
    BJU INTERNATIONAL, 2023, 131 (05) : 553 - 561